about
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosisWT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia.Molecular response in CML: where is the bar?The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party.Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model.Molecular therapy for multiple myeloma.IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemiaChronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaPhiladelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosisBCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.New tyrosine kinase inhibitors in chronic myeloid leukemia.Dual tyrosine kinase inhibitors in chronic myeloid leukemia.BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationshipsAssociation between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Best Practices in Chronic Myeloid Leukemia Monitoring and ManagementEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseImatinib mesylate for the treatment of chronic myeloid leukemia.The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysisPancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance.Response definitions and European Leukemianet Management recommendations.New targets for Ph+ leukaemia therapy.New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
P50
Q27851487-8DB9FB6D-6B2C-4A02-BE27-6BC4561B3C7AQ28678649-DEE3C74F-FE2E-41F5-88ED-225D84A7226BQ33284886-9A4A4CDD-C735-4EBB-B539-C9AB24B0CEAAQ33431360-E4196D96-D966-4489-84FD-FF26148BD6FAQ33728189-9C9985DB-9EA9-407F-AA49-AB420B18A186Q33849578-C3046C8C-EADC-4592-8B3F-9937C29236E8Q33948671-0DE4B2FA-9859-4E97-BC5C-5819C6E3FA6FQ34166538-D20F2C85-E2B3-470F-BABF-93AE65B7C285Q34308571-5C1C6F1A-9510-496D-A829-F97EACA1F8B8Q34353508-2B5DCCA8-B994-44EB-8FD9-0287B5F397EBQ34358106-91252449-A5AC-41EE-8ABE-D6C6FE85F5ECQ34642865-CCA91EEC-3622-4535-9B28-378DB22195CAQ34644820-F7D63871-7672-4E30-950C-2A5294ED148EQ34750545-E0A5FC84-B6E3-4F23-AD38-1F6FC6DC97AEQ35067505-6299EC65-4FF9-4A88-B2C5-B8BD741F0889Q35683215-85C2125F-24B6-4839-9708-C283D72A7357Q35849776-5F850070-EEF4-4ED9-957D-96AC1157D0F3Q36006408-B86C44BF-7256-4A5F-BC9F-58E934FE506BQ36093137-FC71D0C4-DD20-4726-BC9A-EA23673C4A64Q36093870-0F6DCBFC-65B5-456E-ADA2-41F625325071Q36265601-04E1CC89-870D-41CE-ABAA-C39DB0CA9000Q36542821-3C8658E7-4087-4BFC-B5A5-BA0650A722FEQ36579071-7B712D63-86A0-4350-9908-157FC2D48CD8Q36599984-6F2E62D5-FAAB-4815-9275-27F13C9BCC5EQ36708942-88D95CCE-2657-4F0F-9E44-66169ED251B3Q36884361-65D00988-C480-4AC4-85A7-708F9E09E970Q37026032-44289AA4-40B8-4CF6-8952-47DAC3230BC4Q37027753-AD1FF513-782A-4CDC-B810-30316ABE820DQ37028628-6C6087CA-D2A1-425B-99D1-23709F0A636BQ37163834-28F8F7D5-028A-488C-8E5E-F98AC24D5768Q37183434-A8962CDB-C895-4609-8D8B-C448E1414692Q37212678-77E3683C-7DB3-4622-986E-90448C84DE25Q37470939-9C0A4B7D-A40C-4886-BD0C-C0A3F4521B30Q37586848-F71D8CF0-0828-4640-9D7A-7CC47F54A1F1Q37644004-ECC2C5BF-B385-4344-B81E-41B9C127592DQ37644029-3AA4816B-6DBB-4101-AF79-7BD768E4FC22Q37810095-2FFB76F7-51AD-4936-8AE5-D31C739638B0Q37874391-930ADECF-26AD-42D1-8082-508872001C6DQ38037648-7338753C-CCEA-4580-BAA2-FD66A8987686Q38057413-0C82B499-625B-4F36-BA1C-850B10261992
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Simona Soverini
@ast
Simona Soverini
@en
Simona Soverini
@es
Simona Soverini
@nl
type
label
Simona Soverini
@ast
Simona Soverini
@en
Simona Soverini
@es
Simona Soverini
@nl
prefLabel
Simona Soverini
@ast
Simona Soverini
@en
Simona Soverini
@es
Simona Soverini
@nl
P106
P21
P214
157147904930579090152
P31
P496
0000-0002-4508-0353
P7859
viaf-157147904930579090152